Taysha (TSHA) CFO Reports Tax-Related Sale of 54,491 Shares at $2.85

Rhea-AI Filing Summary

Taysha Gene Therapies (TSHA) CFO Kamran Alam reported a sale of 54,491 shares on 08/21/2025 at a weighted-average price of $2.85 per share. The filing states the shares were sold pursuant to a "sell-to-cover" arrangement to satisfy income tax liabilities from vested restricted stock units, not an open-market discretionary sale. After the transaction Mr. Alam beneficially owned 1,187,603 shares. The filing is a routine Section 16 Form 4 disclosure documenting insider tax-related share disposals and compliance with reporting requirements.

Positive

• Sale was a sell-to-cover for RSU tax liabilities, indicating the transaction was non-discretionary
• Filing discloses weighted-average price and willingness to provide detailed pricing breakdown, supporting transparency
• Insider reporting appears timely and compliant with Section 16 requirements

Negative

• Insider disposed of 54,491 shares, reducing beneficial ownership to 1,187,603 shares
• Sale occurred at a low single-digit price ($2.85 weighted average), which may reflect recent share price weakness

Insights

Financial Analyst

TL;DR: CFO sold shares to cover RSU taxes; ownership remains material but sale appears non-discretionary.

The 54,491-share disposal at a weighted-average $2.85 reflects a tax-withholding sale from vested restricted stock units rather than an opportunistic trading decision.

This reduces the CFO's share count to 1,187,603 but does not indicate new cashing out beyond tax obligations. For investors, the transaction is informational rather than a signal of company fundamentals.

Corporate Governance Expert

TL;DR: The Form 4 shows compliant insider reporting for a sell-to-cover tax withholding event; governance process appears followed.

The filing discloses the nature of the sale and the weighted-average price range of $2.841 to $2.865, and includes an offer to provide granular pricing details on request, which supports transparency.

No change in executive role or other governance actions are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alam Kamran

(Last) (First) (Middle)

C/O TAYSHA GENE THERAPIES, INC.

3000 PEGASUS PARK DRIVE, STE 1430

(Street)

DALLAS TX 75247

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		S		54,491(1)	D	$2.85(2)	1,187,603	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Kamran Alam	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TSHA insider Kamran Alam report on Form 4?

He reported a sale of 54,491 shares on 08/21/2025 executed as a sell-to-cover to satisfy taxes from vested restricted stock units.

At what price were the TSHA shares sold by the CFO?

The weighted-average price was $2.85 per share, with individual transaction prices ranging from $2.841 to $2.865.

How many TSHA shares does Kamran Alam beneficially own after the sale?

He beneficially owns 1,187,603 shares following the reported transaction.

Was the sale by the TSHA CFO discretionary or for tax withholding?

The filing states the sale was pursuant to a sell-to-cover arrangement to satisfy income tax liabilities from RSU vesting.

Does the Form 4 indicate any change in the CFO's relationship with TSHA?

No; the form continues to identify him as the Chief Financial Officer with no role changes disclosed.